Table 1.
Demographics and clinical characteristics.
| Cancer | Cancer | p-Value # | Healthy | p-Value * | ||||
|---|---|---|---|---|---|---|---|---|
| Primary Series of Vaccination | CoronaVac-ChAdOx1 | ChAdOx1-ChAdOx1 | CoronaVac-ChAdOx1 | |||||
| (n = 44) | (n = 87) | (n = 107) | ||||||
| Age, years, median (IQR) | 57 | (48.5–65) | 57 | (48–65) | 0.774 | 41 | (35–48) | <0.001 |
| Sex | ||||||||
| Female | 24 | (55%) | 47 | (54%) | 0.955 | 46 | (43%) | 0.196 |
| Male | 20 | (45%) | 40 | (46%) | 61 | (57%) | ||
| BMI, kg/m2, median (IQR) | 21.7 | (19.5–25.5) | 23.1 | (21–26) | 0.238 | |||
| Cancer types | ||||||||
| Breast | 18 | (41%) | 36 | (41%) | 0.108 | |||
| Colorectal | 11 | (25%) | 33 | (38%) | ||||
| Head Neck | 6 | (14%) | 4 | (5%) | ||||
| Hepato-Biliary-Pancreatic | 4 | (9%) | 5 | (6%) | ||||
| Esophagus/Gastric | 3 | (7%) | 1 | (1%) | ||||
| Genitourinary | 2 | (5%) | 2 | (2%) | ||||
| Lung | 0 | (0%) | 4 | (5%) | ||||
| Other | 0 | (0%) | 2 | (2%) | ||||
| Cancer treatment | ||||||||
| Chemotherapy | 29 | (66%) | 68 | (78%) | 0.131 | |||
| Hormonal therapy/Biologics | 15 | (34%) | 19 | (22%) | ||||
| Corticosteroid | ||||||||
| No/pre-medication | 41 | (93%) | 86 | (99%) | 0.110 | |||
| Therapeutic purpose | 3 | (7%) | 1 | (1%) | ||||
| Disease status | ||||||||
| Early | 20 | (45%) | 39 | (45%) | 0.695 | |||
| Locally advanced | 8 | (18%) | 11 | (13%) | ||||
| De novo metastasis | 10 | (23%) | 27 | (31%) | ||||
| Recurrence | 6 | (14%) | 10 | (11%) | ||||
| Co-morbidity | ||||||||
| Diabetes | 6 | (14%) | 11 | (13%) | 0.873 | |||
| Hypertension | 12 | (27%) | 18 | (21%) | 0.397 | |||
| Cardiovascular disease | 3 | (7%) | 2 | (2%) | 0.334 | |||
| Respiratory tract disease | 1 | (2%) | 2 | (2%) | 1.000 | |||
| Interval between first to second vaccine, days | 24 | (21–28) | 70 | (56–77) | <0.001 | 27 | (21–28) | 0.153 |
| Interval between second to third vaccine, days | 127.5 | (113.5–137) | 118 | (107–136) | 0.306 | 131 | (106–138) | 0.854 |
| Interval between third dose to blood collection, days | 14 | (14–14) | 14 | (14–14) | 0.211 | 14 | (14–14) | 0.544 |
| Type of third vaccine | ||||||||
| BNT162b2 (Pfizer) | 20 | (45%) | 31 | (36%) | 0.276 | 55 | (51%) | 0.507 |
| mRNA-1273 (Moderna) | 24 | (55%) | 56 | (64%) | 52 | (49%) | ||
# Comparison between the primary CoronaVac/ChAdOx1 and ChAdOx1/ChAdOx1 regimen in cancer patients. * Comparison between healthy and cancer patients who received the primary heterologous CoronaVac/ChAdOx1 regimen.